Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Position Increased by First Hawaiian Bank

First Hawaiian Bank increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 14.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 20,400 shares of the medical equipment provider’s stock after acquiring an additional 2,500 shares during the quarter. First Hawaiian Bank’s holdings in Zimmer Biomet were worth $2,155,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZBH. Dunhill Financial LLC boosted its holdings in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in shares of Zimmer Biomet during the 3rd quarter worth $28,000. Bangor Savings Bank purchased a new stake in Zimmer Biomet during the third quarter valued at about $31,000. Brooklyn Investment Group acquired a new position in shares of Zimmer Biomet in the third quarter worth about $35,000. Finally, Quarry LP purchased a new position in shares of Zimmer Biomet in the second quarter worth approximately $53,000. 88.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on ZBH. Barclays reduced their target price on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a report on Thursday, December 12th. Wells Fargo & Company raised their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. BTIG Research dropped their target price on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a report on Thursday, October 3rd. Oppenheimer decreased their price target on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a report on Tuesday, October 15th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, October 31st. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $123.33.

Zimmer Biomet Stock Down 1.7 %

Shares of Zimmer Biomet stock opened at $101.41 on Thursday. Zimmer Biomet Holdings, Inc. has a 12-month low of $100.67 and a 12-month high of $133.90. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The stock has a 50 day moving average price of $108.20 and a two-hundred day moving average price of $108.10. The stock has a market capitalization of $20.19 billion, a P/E ratio of 19.28, a PEG ratio of 1.96 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.74. The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. Zimmer Biomet’s revenue was up 4.1% compared to the same quarter last year. During the same period last year, the business posted $1.65 EPS. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.95%. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.